Mangalam Drugs [MANGALAM] vs Lotus Eye Hospital [LOTUSEYE] Detailed Stock Comparison
Mangalam Drugs
NSE
Loading...
Lotus Eye Hospital
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Mangalam Drugs wins in 11 metrics, Lotus Eye Hospital wins in 7 metrics, with 0 ties. Mangalam Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Mangalam Drugs | Lotus Eye Hospital | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 19.47 | 325.00 | Mangalam Drugs |
| Price-to-Book Ratio | 0.78 | 3.64 | Mangalam Drugs |
| Debt-to-Equity Ratio | 64.59 | 5.72 | Lotus Eye Hospital |
| PEG Ratio | -0.03 | -24.38 | Lotus Eye Hospital |
| EV/EBITDA | 8.56 | 62.47 | Mangalam Drugs |
| Profit Margin (TTM) | -3.27% | 1.32% | Lotus Eye Hospital |
| Operating Margin (TTM) | -15.65% | 4.86% | Lotus Eye Hospital |
| EBITDA Margin (TTM) | N/A | 4.86% | N/A |
| Return on Equity | 4.51% | 1.23% | Mangalam Drugs |
| Return on Assets (TTM) | 1.83% | 1.06% | Mangalam Drugs |
| Free Cash Flow (TTM) | $223.93M | $-21.28M | Mangalam Drugs |
| 1-Year Return | -41.64% | 56.54% | Lotus Eye Hospital |
| Price-to-Sales Ratio (TTM) | 0.42 | 4.31 | Mangalam Drugs |
| Enterprise Value | $2.18B | $2.16B | Mangalam Drugs |
| EV/Revenue Ratio | 0.73 | 4.31 | Mangalam Drugs |
| Gross Profit Margin (TTM) | 20.07% | 49.70% | Lotus Eye Hospital |
| Revenue per Share (TTM) | $189 | $24 | Mangalam Drugs |
| Earnings per Share (Diluted) | $-6.17 | $0.32 | Lotus Eye Hospital |
| Beta (Stock Volatility) | 0.04 | 0.43 | Mangalam Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Mangalam Drugs vs Lotus Eye Hospital Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Mangalam Drugs | -0.21% | -9.17% | -16.96% | -6.81% | -19.17% | -37.93% |
| Lotus Eye Hospital | 6.98% | 19.43% | 58.23% | 62.21% | 97.03% | 68.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Mangalam Drugs | -41.64% | -48.62% | -43.84% | -7.76% | 374.76% | 120.80% |
| Lotus Eye Hospital | 56.54% | 80.45% | 280.59% | 827.30% | 616.81% | 227.74% |
Performance & Financial Health Analysis: Mangalam Drugs vs Lotus Eye Hospital
| Metric | MANGALAM | LOTUSEYE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.25B | ₹2.16B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 42,985 | 368,373 |
| 90 Day Avg. Volume | 37,395 | 133,847 |
| Last Close | ₹74.30 | ₹116.84 |
| 52 Week Range | ₹70.10 - ₹140.50 | ₹54.99 - ₹118.99 |
| % from 52W High | -47.12% | -1.81% |
| All-Time High | ₹442.40 (Dec 07, 2015) | ₹118.99 (Aug 29, 2025) |
| % from All-Time High | -83.21% | -1.81% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.25% | 0.05% |
| Quarterly Earnings Growth | -0.25% | -0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.03% | 0.01% |
| Operating Margin (TTM) | -0.16% | 0.05% |
| Return on Equity (TTM) | 0.05% | 0.01% |
| Debt to Equity (MRQ) | 64.59 | 5.72 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹100.32 | ₹28.54 |
| Cash per Share (MRQ) | ₹1.64 | ₹1.98 |
| Operating Cash Flow (TTM) | ₹24.29M | ₹5.77M |
| Levered Free Cash Flow (TTM) | ₹67.21M | ₹7.39M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Mangalam Drugs vs Lotus Eye Hospital
| Metric | MANGALAM | LOTUSEYE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 19.47 | 325.00 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -0.03 | -24.38 |
| Price to Sales (TTM) | 0.42 | 4.31 |
| Price to Book (MRQ) | 0.78 | 3.64 |
| Market Capitalization | ||
| Market Capitalization | ₹1.25B | ₹2.16B |
| Enterprise Value | ₹2.18B | ₹2.16B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.73 | 4.31 |
| Enterprise to EBITDA | 8.56 | 62.47 |
| Risk & Other Metrics | ||
| Beta | 0.04 | 0.43 |
| Book Value per Share (MRQ) | ₹100.32 | ₹28.54 |
Financial Statements Comparison: Mangalam Drugs vs Lotus Eye Hospital
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MANGALAM | LOTUSEYE |
|---|---|---|
| Revenue/Sales | ₹727.77M | ₹135.17M |
| Cost of Goods Sold | ₹353.65M | ₹67.99M |
| Gross Profit | ₹374.12M | ₹67.18M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹54.54M | ₹6.57M |
| EBITDA | ₹103.69M | ₹16.64M |
| Pre-Tax Income | ₹16.35M | ₹7.30M |
| Income Tax | ₹15.75M | ₹1.85M |
| Net Income (Profit) | ₹594,000 | ₹5.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MANGALAM | LOTUSEYE |
|---|---|---|
| Cash & Equivalents | ₹25.89M | ₹20.11M |
| Total Current Assets | ₹1.99B | ₹115.70M |
| Total Current Liabilities | ₹1.92B | ₹74.25M |
| Long-Term Debt | ₹117.49M | ₹20.27M |
| Total Shareholders Equity | ₹1.49B | ₹600.00M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹1.34B | ₹539.42M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MANGALAM | LOTUSEYE |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MANGALAM | LOTUSEYE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 42,985 | 368,373 |
| Average Daily Volume (90 Day) | 37,395 | 133,847 |
| Shares Outstanding | 15.83M | 20.80M |
| Float Shares | 7.18M | 6.95M |
| % Held by Insiders | 0.56% | 0.65% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Mangalam Drugs vs Lotus Eye Hospital
| Metric | MANGALAM | LOTUSEYE |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.33 |
| 3-Year Avg Dividend Yield | N/A | 0.66% |
| 3-Year Total Dividends | ₹0.00 | ₹1.00 |
| Ex-Dividend Date | N/A | Sep 18, 2023 |